As­traZeneca scores new goal on the pipeline front, adding its first AI-gen­er­at­ed tar­get to the port­fo­lio

As more and more bio­phar­mas de­vel­op ar­ti­fi­cial in­tel­li­gence plat­forms, the drug dis­cov­ery process is be­ing re­shaped to fit new goals on cut­ting down the prodi­gious amount of time, en­er­gy and mon­ey that go in­to a drug pro­gram. Now one of the most am­bi­tious play­ers in the dri­ve to im­prove on ROI, As­traZeneca, is mark­ing a mile­stone on that front by adding the first tar­get gen­er­at­ed by AI to its port­fo­lio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.